The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Should we treat patients with high tumor burden FL with a chemo-free regimen?

Dec 12, 2019

During the 61st American Society of Hematology (ASH) meeting in Orlando, US, the Lymphoma Hub were pleased to speak to Loretta Nastoupil, MD Anderson Cancer Center, Houston, US. We asked: Should we treat patients with high tumor burden follicular lymphoma with a chemotherapy-free regimen?

Loretta Nastoupil discusses the results of a single-center, phase II study that examines the efficacy and safety of obinutuzumab in combination with lenalidomide in high tumor burden, untreated, follicular lymphoma patients. She explains the results demonstrated rapid and high response rates and maintained a similar safety profile as previous studies of rituximab in combination with lenalidomide

Should we treat patients with high tumor burden FL with a chemo-free regimen?